PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
50 hedge funds and large institutions have $35.4M invested in PLx Pharma Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 21 reducing their positions, and 15 closing their positions.
10% less call options, than puts
Call options by funds: $860K | Put options by funds: $954K
12% less funds holding
Funds holding: 57 → 50 (-7)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
48% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 21
67% less capital invested
Capital invested by funds: $106M → $35.4M (-$70.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$612K |
| 2 |
SC
Shay Capital
New York
|
+$486K |
| 3 |
SRC
Shufro Rose & Co
New York
|
+$184K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$137K |
| 5 |
CC
Clearline Capital
New York
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$20.6M |
| 2 |
FA
Friess Associates
Greenville,
Delaware
|
-$2.23M |
| 3 |
Millennium Management
New York
|
-$1.15M |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$572K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$533K |
PLXP Hedge Fund Activity: Q1 2022 in Review
50 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q1 2022, worth a combined $35.4M — down 67% from $106M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PLXP and 9 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 11 added.
The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $612K. The largest seller was MSD Partners, cutting an estimated $20.6M.
- 50 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q1 2022, down from 57 in Q4 2021.
- Funds reported $35.4M of PLx Pharma Inc. Common Stock stock for Q1 2022, down 67% quarter-over-quarter.
- 9 funds opened new PLx Pharma Inc. Common Stock positions in Q1 2022 and 15 closed out, a net change of -6 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q1 2022 was D.E. Shaw & Co, an estimated $612K added.
- The largest PLx Pharma Inc. Common Stock seller in Q1 2022 was MSD Partners, an estimated $20.6M sold.
Based on aggregated 13F filings for Q1 2022.